Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

CVRM product development global head and senior vice-president Manu Chakravarthy will be the centre's site head.

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...

The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...